A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs RPL 554 (Primary) ; Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 09 Sep 2017 Status changed from active, no longer recruiting to completed.
- 07 Sep 2017 Results presented in an Arix Bioscience media release.
- 07 Sep 2017 Primary endpoint (Average FEV1 on the third day of dosing) has been met according to Verona Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History